New kid on the block: Roger Perl­mut­ter's biotech signs on as an­chor ten­ant to new Bay Area cam­pus

Last week
Startups

Abu Dhabi's health de­part­ment taps Sanofi in clin­i­cal re­search and AI screen­ing deal

Last week
Deals
Pharma

Reg­u­lat­ing new re­gen­er­a­tive ther­a­pies: FDA kicks off the process of rec­og­niz­ing vol­un­tary stan­dards

Last week
Cell/Gene Tx
FDA+

Men­tal health cri­sis fol­lows Covid pan­dem­ic in US, but phar­ma miss­ing con­nec­tions to younger gen­er­a­tions, study finds

Last week
Pharma
Marketing

As PD-(L)1 dis­rup­tors suf­fer set­backs, Check­point touts an­oth­er win

Last week
R&D

Gold­man Sachs leads a $300M round in­to a Chi­na biotech uni­corn boast­ing of its AI/ro­bot­ics prowess

Last week
Deals
R&D

A per­pet­u­al los­er at the high stakes game of Alzheimer's re­search, Roche con­cedes an­oth­er amy­loid flop

Last week
R&D

Bio­gen Foun­da­tion dou­bles down on next gen­er­a­tion STEM neu­ro­science to kick off its next decade

Last week
Pharma
Marketing

Supreme Court rules in fa­vor of hos­pi­tals over Medicare re­gard­ing 340B re­im­burse­ment pol­i­cy

Last week
Pharma
Law

Pharm­Stars dig­i­tal health match­mak­er adds Roche to phar­ma spon­sor team as it preps a new chal­lenge

Last week
Pharma
Marketing

Sen­ate com­mit­tee ad­vances FDA user fee bill with ac­cel­er­at­ed ap­proval re­forms

Last week
FDA+

Brief­ing docs for Aca­di­a's Alzheimer's-re­lat­ed psy­chosis re­sub­mis­sion re­veal an un­de­cid­ed FDA

Last week
FDA+

Pfiz­er's Paxlovid does­n't stack up as well for those who are vac­ci­nat­ed, new da­ta show

Last week
Coronavirus

Cannes Li­ons 2022: Phar­ma and health cre­atives ea­ger to re­turn in per­son, ready to min­gle with main­stream ad crowd

Last week
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er keeps spot­light on JAKs with Cib­in­qo TV ad; Dex­com amps di­a­betes aware­ness in UK ef­fort

Last week
Pharma
Marketing

Lil­ly's Olu­mi­ant gets new FDA ap­proval, nab­bing a land­mark green­light for au­toim­mune hair loss dis­ease

Last week
Pharma
FDA+

In draft re­port, ICER says Amy­lyx's ALS drug would not be cost ef­fec­tive if priced sim­i­lar­ly to old­er treat­ment

Last week
R&D
Pharma

Ameet Mallik taps fel­low No­var­tis alum to lead busi­ness de­vel­op­ment at ADC Ther­a­peu­tics

Last week
People

Up­dat­ed: Al­ny­lam scores OK for sec­ond-gen hAT­TR ther­a­py as the space heats up

Last week
Pharma
FDA+

CBER to in­dus­try: Nor­mal op­er­a­tions will re­sume in 2023

Last week
FDA+

With pan-RAF drug from Take­da, Day One un­veils its first pe­di­atric brain can­cer da­ta. And the mar­ket loves it

Last week
R&D

FDA of­fers sup­port for Pfiz­er, Mod­er­na Covid-19 vac­cines for the youngest chil­dren ahead of ad­comm

Last week
FDA+
Coronavirus

Amy­lyx picks up ALS drug ap­proval in Cana­da af­ter FDA asks for more time to re­view the da­ta

Last week
R&D
FDA+

A biotech up­start just scored $103M from Pfiz­er et al to fu­el its pur­suit of a new (to you) I/O path­way

Last week
Financing
First page Previous page 123456 Next page Last page